Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 802
Aptamer sequence: GGGAGCUCAGAAUAAACGCUCAAAUCCGUGGACAGGGCGUAAGCGCCUUCGACAUGAGACACGGAUCCUGCGACGAAUUCAGC
Target unique ID: 6287
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_723 N Molecule Valine 12 mM 25 mM HEPES, 200 mM NaCl, 6 mM MgCl2, 1 mM EDTA (pH 7.3) 7545073
Structure information of aptamer
Aptamer Sequence: GGGAGCUCAGAAUAAACGCUCAAAUCCGUGGACAGGGCGUAAGCGCCUUCGACAUGAGACACGGAUCCUGCGACGAAUUCAGC
The optimal secondary structure in dot-bracket notation: ....(((..((((...(((....(((((((..(((((((....)))))......))...)))))))...)))....)))))))
The centroid secondary structure in dot-bracket notation: ....(((..((((...(((....(((((((....(((((....)))))...........)))))))...)))....)))))))
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_723 Description N
Aptamer chemistry RNA Length 83 nt
GC content 55.4% Molecular weight 26,818.06 Da
Molarity of 1 μg/μl solution 37.29 μM Number of G-quadruplexes No QGRS found
G-Score N/A Function Targeted binding
Sequence GGGAGCUCAGAAUAAACGCUCAAAUCCGUGGACAGGGCGUAAGCGCCUUCGACAUGAGACACGGAUCCUGCGACGAAUUCAGC
Applications Binding to valine
Target information
Type Detail Type Detail
PubChem ID 6287 Molecular name Valine
Molecular formula C5H11NO2 Molecular weight 117.15
IUPAC name (2S)-2-amino-3-methylbutanoic acid InChIKey KZSNJWFQEVHDMF-BYPYZUCNSA-N
LogP 0.054 Topological polar surface area 63.32
Hydrogen bond acceptor 2 Hydrogen bond donor 2

Synonym(s):
L-valine; valine; 72-18-4; (S)-Valine; H-Val-OH; (S)-2-Amino-3-methylbutanoic acid; 2-Amino-3-methylbutyric acid; (2S)-2-amino-3-methylbutanoic acid; (S)-2-Amino-3-methylbutyric acid; L-alpha-Amino-beta-methylbutyric acid; Valinum [Latin]; Valina [Spanish]; Valine (VAN); Butanoic acid, 2-amino-3-methyl-; Valine [USAN:INN]; L-valin; VALINE, L-; L(+)-alpha-Aminoisovaleric acid; (S)-alpha-Amino-beta-methylbutyric acid; Butanoic acid, 2-amino-3-methyl-, (S)-; 2-Amino-3-methylbutyric acid, (S)-; 2-Amino-3-methylbutanoic acid, (S)-; UNII-HG18B9YRS7; NSC 76038; (L)-valine; 2-Amino-3-methylbutanoic acid (VAN); 7004-03-7; CHEBI:16414; L-2-Amino-3-methylbutanoic acid; l-(+)-alpha-Aminoisovaleric acid; L-2-Aminoisovaleric Acid; MFCD00064220; val; valina; HG18B9YRS7; (S)-alpha-Aminoisovaleric acid; NSC-76038; Valine (L-Valine); L-Val; Valinum; 2-aminoisovaleric acid; (2S)-2-amino-3-methylbutanoate; alpha-aminoisovaleric acid; EINECS 200-773-6; 2-Amino-3-methyl-butyric acid; 2-amino-3-methylbutanoate; Racemic valine; L-(+)-a-Aminoisovaleric acid; s-valin; L-(+)-.alpha.-Aminoisovaleric acid; L-a-Amino-b-methylbutyric acid; HSDB 7800; 3h-l-valine; (S)-a-Amino-b-methylbutyric acid; L-Valine;; L-Valine, FCC; Valine (USP); (+)-valine; L-Valine,(S); 1t4s; L-Valine (JP17); L-Valine, 99%; (S)-Val; L-Val-4; L-VAL-OH; 2-Amino-3-methylbutyrate; bmse000052; bmse000811; bmse000860; EC 200-773-6; L-(+)-a-Aminoisovalerate; L-a-Amino-b-methylbutyrate; SCHEMBL8516; (S)-A-Aminoisovaleric acid; H-Val-2-Chlorotrityl Resin; (S)-?-Aminoisovaleric acid; 2-Aminoisovaleric acid,(S); CHEMBL43068; (S)-a-Amino-b-methylbutyrate; L-(+)-alpha-Aminoisovalerate; L-iso-C3H7CH(NH2)COOH; GTPL4794; (S)-2-Amino-3-methylbutyrate; (S)-2-Amino-3-methylbutanoate; L-Valine, Cell Culture Reagent; DTXSID40883233; L-alpha-Amino-beta-methylbutyrate; (S)-2-amino-3-methyl-Butanoate; Pharmakon1600-01301009; ZINC895099; HY-N0717; (S)-alpha-Amino-beta-methylbutyrate; (S)-2-amino-3-methyl-butyric acid; BDBM50463208; NSC760111; s5628; (S)-2-amino-3-methyl-Butanoic acid; L-Valine, 98.5-101.5%; AKOS015841564; AM82363; CCG-266067; CS-W020706; DB00161; L-Valine, 99%, natural, FCC, FG; MCULE-9143825935; NSC-760111; NCGC00344520-01; AS-12787; K180; L-Valine, BioUltra, >=99.5% (NT); L-Valine, SAJ special grade, >=98.5%; AB0014076; DB-029989; L-Valine, reagent grade, >=98% (HPLC); L-Valine, Vetec(TM) reagent grade, >=98%; C00183; D00039; M02950; V-1800; (S)-(+)-2-AMINO-3-METHYLBUTYRIC ACID; 064V220; 192321-EP2272829A2; Q483752; Q-100919; L-Valine, certified reference material, TraceCERT(R); F8889-8698; Valine, European Pharmacopoeia (EP) Reference Standard; Z1250208665; 1B39571B-0AE8-4A9A-AE80-4B898D11A981; L-Valine, dimer, meets the analytical specifications of USP; UNII-0O72R8RF8A component KZSNJWFQEVHDMF-BYPYZUCNSA-N; UNII-4CA13A832H component KZSNJWFQEVHDMF-BYPYZUCNSA-N; UNII-66PZQ62YA6 component KZSNJWFQEVHDMF-BYPYZUCNSA-N; UNII-N7U7BXP2OI component KZSNJWFQEVHDMF-BYPYZUCNSA-N; L-Valine, United States Pharmacopeia (USP) Reference Standard; L-Valine, Pharmaceutical Secondary Standard; Certified Reference Material; L-Valine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%; L-Valine, PharmaGrade, Ajinomoto, EP, JP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture

Activity data

No relevant experimental diagram

Interaction ID 802
Target type Molecule
Target unique ID 6287
Activity 12 mM
Binding Conditions/Buffer

25 mM HEPES, 200 mM NaCl, 6 mM MgCl2, 1 mM EDTA (pH 7.3)

Assay

N/A

PubMed ID 7545073
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_171 RNA GGGAGCUCAGAAUAAACGCUCAACCAGUCUUGUGGCUUUGAAAGAGAGGAGUGUUCGACAUGAGGCCCGGAUCCGGC 61.45%
Apta_432 RNA GGGAGACAAGAAUAAACGCUCAAGGCAUUUCUGCUAGUCUGGUUGUAAGAUAUUCAACACGUGAGUUUCGACAGGAGGCUCACAACAGGC 61.11%
Apta_854 RNA GGGAGCUCAGAAUAAACGCUCAAGGGUAGGGAUCGUUACCCCGACAUUUUAAUGGGCCGAUGUUUCGACAUGAGGCCCGGAUCCGGC 60.92%
Apta_433 RNA GGGAGACAAGAAUAAACGCUCAACGUUCAGUAUAACAGUCCGAGUCUAACACACAAUGGGACACUGAAUUCGACAGGAGGCUCACAACAGGC 59.78%
Apta_137 RNA GGGAGACAAGAAUAAACGCUCAAGUGACGUCCUGAUCGAUUGUGCAUUCGGUGUGACGAUCUUUCGACAGGAGGCUCACAACAGGC 59.30%
Apta_398 RNA GGGAGGACGAUGCGGCUUUAAUCCUCGCACUCAGCGCGCAUCACCCUUGACAUCACAGACGACUCGCUGAGGAUCCGAGA 57.83%
Apta_256 RNA GGGCGCUAAGUCCUCGCUCAUGCGCGUCCCAUGGGGUAUAGAGGGGUCGAAGUGGACGCGCGACUCGGAUCCU 56.63%
Apta_502 DNA GGGAGACAAGAATAAACGCTCAAATGGACTTTTGAATGTGGCAACAAATTCGACAGGAGGCTCACAACAGGC 56.63%
Apta_790 DNA GGGAGACAAGAATAAACGCTCAAGAAGTGAAAATGACAGAACACAACATTCGACAGGAGGCTCACAACAGGC 56.63%
Apta_886 RNA GGGAGACGAUAUUCGUCCAUUCGGGUGGCCCGUGUCUGAGCGGGGACGGCCACUUGAGCGCCGCUGUCCGACUGAAUUCUCGACC 56.47%
Apta_272 RNA GGGAGACAAGAAUAAACGCUCAACACAGAACGCGGUCCCCACACAGGACAGGAGCCAGCCCCGGUUCGACAGGAGGCUCACAACAGGC 55.68%
Apta_170 RNA GGGAGACAAGACUAGACGCUCAAUGUGGGCCACGCCCGAUUUUACGCUUUUACCCGCACGCGAUUGGUUUGUUUCCC 55.42%
Apta_305 RNA GGGAGGACGAUGCGGAUCGCCCUGAACCGGCCCAGCAGACUGCUGACGGCACGAUCCGCAUCGUCCUCCC 55.42%
Apta_1223 RNA GGAGGCGCCAACUGAAUGAAAGGUUACGCUUCAACGCCGUGCAGCUGCUUCGGCAGGCUUGUGAGUACAUGGCCCAUUGAUCCGUAACUAGUCGCGUCAC 55.00%
Apta_1222 RNA GGAGGCGCCAACUGAAUGAAACCGUGCUAAGGAGUUGGACUCCGCUGCUUCGGCAGAGCGAUAUAGUGCCAGCUGAUACAUCCGUAACUAGUCGCGUCAC 54.00%
Apta_1224 RNA GGAGGCGCCAACUGAAUGAAUGUUCUGGAUCUGCUAGAGACUAUCUGCUUCGGCAGCACUCUCCGUUAACAACACGUACAUCCGUAACUAGUCGCGUCAC 54.00%
Apta_936 RNA GGAGCUCAGCCUUCACUGCGAUCACCGUGUCGGUGGCUAGUCGAUGUAUCCCGAUCACCAUUGGGGGCAAGUUUAGACAGGCACCACGGUCGGAUCCAC 53.54%
Apta_123 RNA GGGAGAAAGGGAAGCUUGAGCAGCAGGAGGGCCGGCGUUAGGGUUAGCGAGCCGAUUGAAAGAAGAAGGAACGAGCGUACGGAUCCGAUC 53.33%
Apta_380 RNA GGGAUGCUUCGGCAUCCCCGAAGCCGCUAUGGACCAGUGGCGCGGCUUCGGCCCGACGGAGUGGUACCGCUUCGGCGGUACGUAAGCUUGGG 53.26%
Apta_397 RNA GGGAGGACGAUGCGGAUACCAGGAUCACAUCCUGAGGAACCCCGGCUCCCAACCUCAGACGACUCGCUGAGGAUCCGAGA 53.01%